Loading this company
Eli Lilly and Company
LLYPrices in USD
TickerWorth ScoreC53/100
What we think
Priced within our range of $607.91 to $1,297.64.
Price
$1,257.03USD up +$5.42 (+0.43%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 2 models, on today’s numbers
$607.91–$1,297.64
What the price needs: revenue growth of 14.8%/yr for 5 years (our model assumes 16.6%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $1,257.03Priced · Prices are delayed.
Is it a good business?
- Valuation0 out of 100
- Growth100 out of 100
- Financial health33 out of 100
- Dividend75 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$1,328.05 across 30 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in United States. The company employs roughly 50,000 people.
Revenue: United States 67% · Europe 18% · Rest of world 9% · JAPAN 3% · 1 more
Key stats
52-week range$793.82–$1,292.65
- Open
- $1,256.00
- Day high
- $1,274.56
- Day low
- $1,251.25
- Previous close
- $1,251.61
- Volume
- 2,406,073 · 0.97× avg
- Average volume
- 2,472,935
- Market cap
- $1,120,462,569,472.00
- P/E (TTM)
- 42.20
- Earnings per share
- $29.79
- Beta
- 0.45
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Disclosed another material event
- Reported shareholder vote results
- Reported quarterly or annual results
- Reported quarterly or annual results
- Changed leadership or its board
- Reported quarterly or annual results
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Sulzberger GabrielleGrant / award · $4,958.35
- LUCIANO JUAN RGrant / award ·
Not investment advice. TickerWorth Score is a model output.